In 2017, many high-impact articles appeared in the literature. This is the third edition of an annual review of articles related to postoperative cardiac critical care that may affect the cardiac anesthesiologist. This year explores vasopressor and inotropic support, timing of renal replacement therapy, management of postoperative respiratory insufficiency, and targeted temperature therapy.
Introduction
As in previous years, the authors have reviewed contemporary publications on topics important to cardiothoracic critical care specialists. This is not a comprehensive review of the year's literature but rather a curated collection of relevant articles. We thank the editors for the liberty to select appropriate texts. The topics include vasopressor and inotropic support, treatment of acute kidney injury (AKI), management of respiratory insufficiency, and targeted temperature therapy.
Hemodynamic Management

Vasopressor Choice
Vasoplegia occurs in 5% to 25% of patients following cardiac surgery. 1 Vasopressin, first suggested for treatment of postcardiotomy vasoplegia by Argenziano et al, 2 has been shown to safely raise arterial blood pressure when used as an infusion. 3, 4 Vasopressin has previously been compared to norepinephrine in septic shock patients with mixed results. The VANCS trial (Vasopressin versus Norepinephrine in Patients after Cardiac Surgery) sought to define the relative value of these vasopressors in treating vasoplegic shock. 5 VANCS was a prospective, randomized, double-blind trial comparing the impact of vasopressor selection on outcome. The authors hypothesized that treatment with vasopressin would be more efficacious than norepinephrine in patients experiencing vasoplegic shock after cardiac surgery. All patients undergoing coronary bypass or valve surgery at a single center in Sao Paulo, Brazil were enrolled during a 27-month period. Vasodilatory shock was defined as a mean arterial pressure (MAP) less than 65 mm Hg without response to a minimum fluid challenge of 1 L crystalloid fluid, and a cardiac index higher than 2.2 L/min/m 2 . If a patient required vasopressors for vasoplegia within 48 hours of separation from bypass they were randomized to receive an infusion of the study drug with a target MAP >65 mm Hg. If target pressure could not be reached at the highest titration of study drug, unblinded norepinephrine was added. The primary outcome was a modified Society of Thoracic Surgery model for major adverse events (MAE) after cardiac surgery including stroke, prolonged mechanical ventilation, deep sternal wound infection, reoperation, and acute renal failure.
A total of 330 patients were enrolled. Thirty were excluded because of ongoing treatment with vasopressin or norepinephrine, and the remaining 300 patients were randomized in a near equal distribution (151 vs 149). 5 The primary endpoint, MAE, occurred in a significantly higher percentage of patients in the norepinephrine group versus those randomized to vasopressin (49% vs 32.2%, P = .0014). However, there was no difference in 30-day mortality, ventilation time, sternal wound infection, reoperation, or stroke. 5 The only significant difference between the groups was a higher rate of acute renal failure in the norepinephrine group (35.8% vs 10.3%, P < .0001). The use of open-label norepinephrine as well as total fluid administration and fluid balance were not statistically different between the groups. Finally, vasoplegic patients treated with vasopressin had a much lower incidence of postoperative atrial fibrillation (63.8 % vs 82.1 %, P = .0004). 5 However, the overall incidence of atrial fibrillation in this study, 73%, was much higher than the previously described incidence of approximately 30% in this population. 6 
Inotropic Therapy
Levosimendan, a calcium sensitizer that opens ATPdependent potassium channels, can be used as an alternative inodilator to support the failing heart. Last year Pollesello, et. al., reviewed meta-analyses and randomized controlled trials evaluating the efficacy of levosimendan in a variety of clinical scenarios. 7 Within the field of cardiac surgery, the results of 10 meta-analyses were pooled to define perioperative outcomes associated with Levosimendan use. The authors identified significant benefits when Levosimendan was used, including lower troponin release, lower postoperative mortality, improved cardiac index, reduced intensive care unit (ICU) stay, lower incidence of atrial fibrillation, and less acute kidney injury and need for renal replacement therapy (RRT). 7 The authors concluded that Levosimendan has great promise as an alternative inodilator in cardiac surgery. It should be noted, however, that the lead author and one other had potential conflicts as employees of the drug manufacturer, Orion Pharma (Espoo, Finland).
This year the results of three randomized controlled trials were published on the use of Levosimendan in patients undergoing cardiac surgery. Two appeared in the May issue of the New England Journal of Medicine, the LEVO-CTS trial and the CHEETAH study group trial. 8, 9 The multicenter LEVO-CTS trial was a phase 3 study evaluating the safety and efficacy of Levosimendan in cardiac surgery patients with severely reduced left ventricular function (ejection fraction <35%). 8 A total of 849 patient undergoing cardiopulmonary bypass were randomized to either placebo or Levosimendan administered as a loading dose of 0.2 µg/kg/min for 1 hour followed by an infusion at 0.1 µg/kg/min for 23 hours. Two primary endpoints were calculated. The first was a composite endpoint that included 30-day mortality, RRT in first 30 days, and myocardial infarction or the need for mechanical circulatory support in the first 5 postoperative days. 8 The second was the composite of 30-day mortality and the need for mechanical circulatory support in first 5 postoperative days. Study drug was administered around the time of anesthesia induction. The 2 groups were well matched for demographics, preoperative comorbidities, type of surgery, and intraoperative factors such as crossclamp time and total duration of cardiopulmonary bypass. Use of additional vasopressors or inotropic agents was at the discretion of the provider. However, nesiritide use was prohibited due to its potential for additive hypotension. The trial showed no difference in either primary endpoint between the groups or for any individual element of the composite outcomes. The incidence of hypotension, atrial fibrillation, prolonged ventilation, and congestive heart failure were also similar. 8 One positive finding was a significant association between prophylactic Levosimendan use and a reduction in the incidence of low cardiac output syndrome (18.2% vs 25.7%, P = .007) or the need for inotropes at or beyond 24 hours (54.9% vs 62.7%, P = .02). 8 The CHEETAH group's study yielded similar results. This trial, conducted in 14 centers over a 6.5-year period sought to examine the potential for Levosimendan to alter outcomes in patients following cardiac surgery. 9 Levosimendan was administered without a loading dose as a continuous infusion at 0.025 µg/kg/min. The infusion rate could be increased or decreased at the discretion of the attending physician, up to a maximum dose of 0.2 µg/kg/min for a period of either 48 hours or discharge from the ICU. 9 Thirty-day mortality was similar between groups (12.9% in treatment group vs 12.8% in placebo group). 9 Secondary outcomes were also similar including the incidence of acute kidney injury, need for renalreplacement therapy, duration of ventilation, ICU stay, hospital stay and a composite of any adverse event. The trial was halted for futility after 506 patients failed to demonstrate any difference in primary outcome. 9 The third randomized, double-blind study completed in 2017 was the LICORN trial (Effect of Levosimendan on Low Cardiac Output Syndrome in Patients with Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass). 10 The trial, conducted in 13 French cardiac surgery centers, enrolled 336 patient with an ejection fraction ≤40% undergoing coronary artery bypass graft or coronary artery bypass graft/valve surgery. Study drug (0.1 µg/kg/min) or placebo was administered after anesthetic induction and continued for 24 hours. The results showed no difference in the incidence of 3 postoperative events: prolonged catecholamine infusion, use of mechanical left ventricular support, or RRT.
The LEVO-CTS, CHEETAH, and LICORN trials all failed to demonstrate any significant benefit to Levosimendan use for patients undergoing cardiac surgery. The drug remains unavailable in the United States and has not been approved by The Food and Drug Administration.
Timing of Renal Replacement Therapy
Two recent randomized trials examined the timing of RRT in critically ill patients. The AKIKI trial was performed in 31 centers in France, recruiting 620 critically ill patients who met criteria for Kidney Disease: Improving Global Outcomes (KDIGO) stage 3 AKI, with a diagnosis of acute tubular necrosis. 11 Patients must have been receiving epinephrine or norepinephrine infusion, or mechanical ventilation, or both prior to enrollment. Patients were excluded if they had an absolute indication for RRT such as potassium (K) >6 mEq/L, blood urea nitrogen (BUN) >112 mg/dL, pH < 7.15, hypoxia from pulmonary edema or fluid overload despite diuretic therapy. Preexisting severe chronic kidney disease was also exclusionary. Patients were randomized to either early RRT initiation or delayed RRT initiation. For early initiation, RRT was to start within 6 hours of meeting diagnosis for KDIGO criteria for stage 3 AKI. In the delayed initiation group, RRT was to start only if one or more of the following criteria were met: K >6 mEq/L, BUN >112 mg/dL, pH < 7.15, hypoxia from pulmonary edema and fluid overload, or oligoanuria >72 hours after randomization. The primary outcome was mortality at 60 days following randomization. A total of 311 patients were randomized to early RRT, 308 to delayed RRT, and 1 patient withdrew consent. The recruited patients were 80% medical and 20% surgical. Mean age was 65 years, 10% had chronic renal failure defined as creatinine clearance <60 mL/min, and 80% had a diagnosis of sepsis, severe sepsis, or septic shock. 63% had exposure to nephrotoxins. Sepsis-related Organ Failure Assessment (SOFA) scores were comparable in early and delayed RRT groups, averaging approximately 11. The 2 groups were similar with regard to comorbidities except baseline prothrombin ratio, which was lower in the delayed RRT group.
In the early RRT group, median time from randomization to RRT initiation was 2 hours (interquartile range [IQR] 1-3), whereas in the delayed RRT group it was 57 (IQR 25-83) hours. In the early RRT group, 6 patients did not receive RRT, because of protocol violations or premature death. In the delayed group, 151 (49%) did not ultimately receive RRT because they did not meet initiation criteria. In those receiving delayed RRT, the most common indications for initiating therapy were persistent oligoanuria or BUN >112 mg/dL. The study found no difference in the primary outcome of 60-day, postrandomization mortality with 48.5% expiring (95% confidence interval [CI] 42.6-53.8) in the early RRT group and 49.7% expiring (95% CI 43.8-55.0) in the delayed group. Mortality at day 28, number of mechanical ventilationfree days, vasopressor-free days, length of ICU stay, length of hospital stay, and dependence on RRT at days 28 and 60 were also not significantly different between groups. The delayed RRT group did experience significantly more RRT-free days, and had fewer catheterrelated bloodstream infections. Rate of complications potentially related to AKI or RRT were also not significantly different except for hypophosphatemia, which was more common in the early RRT group. Neither red blood cell transfusion rates nor amount transfused per patient were significantly different between groups.
While the AKIKI trial was applauded for its randomized controlled design, critics raised concerns regarding the substantial portion of the delayed RRT group who never received RRT. In post hoc analyses, the authors acknowledge that the subgroup of no RRT patients had the lowest mortality at day 60 (37.1%), compared with those patients in the delayed group who received RRT (61.8%), and those patients in the early RRT group (48.5%, P < .001). After adjustments were made for baseline severity of illness, the mortality differences were no longer statistically significant between groups, suggesting the critics may have been correct. Ultimately, the AKIKI was unable to demonstrate a difference in outcomes for early versus delayed RRT.
The other contemporary study examining timing of RRT was the ELAIN trial. 12 This study, a German singlecenter randomized trial, recruiting 231 critically ill patients with KDIGO stage 2 AKI as well as plasma neutrophil gelatinase-associated lipocalin level (a biomarker of presence of AKI) >150 ng/mL. Inclusion also required at least one other marker of severe illness: severe sepsis, vasopressor or catecholamine use, refractory fluid overload, or development or progression of nonrenal organ dysfunction measured by SOFA. Patients were randomized to either early or delayed RRT. Early RRT was initiated within 8 hours of diagnosis of KDIGO stage 2 AKI, whereas delayed RRT was initiated within 12 hours of KDIGO stage 3 AKI or if an absolute indication for RRT arose. The primary outcome was overall mortality at 90 days after randomization.
Of the 231 enrolled patients, 112 were randomized to early and 119 to delayed RRT. A majority of patients (95%) were surgical, including cardiac surgery, general surgery, and surgery for trauma. Baseline characteristics were similar. The median time to initiation of RRT was significantly shorter in the early group, 6 hours (IQR 4-7), versus 25.5 hours (IQR 18.8-40.3) in the delayed group. At the time of RRT initiation, serum creatinine and BUN were significantly higher, and urine output lower, in the delayed RRT while white blood cell count, hemoglobin, potassium, and bicarbonate, were similar between early and late groups at time of RRT initiation.
Mortality was significantly lower in the early RRT group (39.3%) compared with the delayed RRT group (54.7%) (P = .03, hazard ratio 0.66). A number of secondary outcomes were also improved in the early RRT group, including median duration of RRT (9 vs 25 days), rate of recovery of renal function (53.6% vs 38.7%), median duration of mechanical ventilation (125.5 vs 181 hours), and length of hospital stay (51 vs 82 days). Subgroup analyses were also performed comparing the delayed RRT patients who received RRT because of absolute indications to those who received RRT because of progression to stage 3 AKI. Again, no significant differences could be identified with regard to 90-day mortality, duration of RRT, ICU length of stay, or hospital length of stay.
The ELAIN trial, like the AKIKI trial, has significant limitations. It too may be underpowered and as a singlecenter study, more prone to bias and exaggerated treatment effects than a multicenter trial. Moreover, the difference between initiation times of RRT in the early and delayed groups was modest making the significant improvements in mortality appear out of proportion to the differences in treatment.
The conflicting results of both the AKIKI and ELAIN trials have drawn many comparisons. Many have noted that the trials evaluate timing of RRT initiation, but their design and patient populations have important differences. [13] [14] [15] [16] The AKIKI trial's patient population was largely medical, and roughly 80% had sepsis, severe sepsis, or septic shock as diagnoses. On the other hand, the ELAIN trial's patient population was predominantly surgical, with approximately 50% post-cardiac surgery, and another 30% post-general surgery. Only about 30% of the patients in ELAIN had severe sepsis as a diagnosis. The AKI that results from sepsis and perioperative AKI have different pathophysiology and prognosis. It is plausible that postoperative AKI may be more amenable to early treatment with RRT than septic AKI. The 2 studies' patient populations also differed in that the ELAIN trail enrolled more patients with nonrenal organ dysfunction as reflected in SOFA score of 16 versus 11 for AKIKI. Interestingly, ELAIN enrolled a large proportion of patients (>70%) with pulmonary edema as part of their inclusion criteria, while the AKIKI trial specifically used refractory pulmonary edema as exclusion criteria for recruitment. This may suggest that the postoperative patients in ELAIN, with multi-organ dysfunction and fluid overload, perhaps derive more benefit from early RRT initiation. The timing of the "early" RRT group in the 2 studies were also different-early RRT initiation in ELAIN was after stage 2 AKI, while in AKIKI it was after stage 3 AKI. It is plausible there is a "window of opportunity" in early stages AKI to intervene with RRT for there to be an outcome difference. Finally, the type of RRT may have contributed to the difference. In AKIKI, intermittent hemodialysis or continuous RRT (CRRT) were both used, the decision left to the individual medical center. In ELAIN, only CRRT was used. In hemodynamically unstable, vasopressor-dependent critically ill patients, intermittent hemodialysis may worsen their instability and contribute to poorer outcomes.
More recently, 2 meta-analyses examined the timing of RRT initiation in critically ill patients. The first, by Zou et al 17 specifically focused on early versus late RRT initiation in cardiac surgery patients with AKI. A comprehensive literature search identified 15 studies appropriate for inclusion. Outcomes for 1479 patients were collated and analyzed. The authors concluded that early RRT initiation decreases 28-day mortality (odds ratio [OR] 0.36), shortens ICU length of stay (mean difference −2.50, 95% CI −3.53 to −1.47), shortens hospital length of stay (mean difference −0.69, 95% CI −1.13 to −0.25), and reduces RRT duration (mean difference −1.18, 95% CI −2.26 to −0.11) especially when RRT was initiated within 12 hours. However, the inclusion of results of many small trials, and the exclusion of ELAIN, which was not specifically cardiac surgery patients, suggest that interpretation of these data should be performed cautiously.
Another meta-analysis by Lai et al 18 looked at early versus later initiation of RRT in critically ill patients with AKI. In contrast to the study by Zou et al, 17 this metaanalysis included only randomized controlled trials (RCTs). Nine RCTs were identified including a total of 1627 participants. Both ELAIN and AKIKI were included. The authors found that earlier RRT was not associated with improvements in mortality (relative risk [RR] 0.88, 95% CI 0.68-1.14, P = .33), RRT dependence (RR 0.81, 95% CI 0.46-1.42, P = .46), and ICU or hospital length of stay. However, in a subgroup analysis, this meta-analysis did find that earlier RRT was associated with decreased in-hospital mortality in surgical patients (RR 0.78), as well as in patients who experienced CRRT (RR 0.80, 95% CI 0.67-96). 18 The question of early versus delayed RRT initiation in critically ill patients has not been definitively answered. The heterogeneous patient populations and differences in study methodology make it difficult to generalize these results across larger populations. Future studies including larger sample sizes, in specific patient populations such as after cardiac surgery, may be necessary to understand whether there is a benefit to early versus delayed RRT.
High-Flow Nasal Cannula Applications in Hypoxemic Respiratory Failure After Cardiac Surgery
Hypoxemic postoperative respiratory insufficiency is seen in up to 20% of patients requiring mechanical ventilation in the postoperative setting. 19 When it occurs following cardiothoracic surgery, morbidity and mortality may be increased. 20, 21 High-flow nasal cannula (HFNC) and conventional oxygen therapy (COT) are commonly used strategies to treat this threatening condition. However, the relative efficacy of each therapy has been difficult to discern. Recent meta-analyses aimed at sorting out the superiority of either of these therapies favor HFNC. Patients seem to tolerate HFNC better than COT with both dyspnea and comfort scores favoring this more aggressive approach to postoperative hypoxia. Reintubation rates were also improved when using HFNC. However, the data has yet to show any mortality benefit of HFNC over COT in the postoperative setting. Fortunately, one recent RCT made the effort to resolve this ongoing debate. 22 In 2016, Hernandez et al 23, 24 published 2 randomized clinical trials in the Journal of the American Medical Association, examining the role of HFNC on reintubation and postextubation respiratory failure in both low-and high-risk patients. 23, 24 In patients at low risk for reintubation, HFNC was superior to COT. 23 Patients at high risk for reintubation were not offered COT but instead were treated with either noninvasive mechanical ventilation (NIMV) or HFNC. HFNC was found to be noninferior to NIMV in reducing the need for reintubation. 24 More recent meta-analyses support the results reported in these 2 RCTs. Zhao et al 25 recently reviewed the results of 11 RCTs in adult patients with respiratory failure. HFNC was compared with COT and NIMV. 25 A total of 3459 patients were included in the analysis. HFNC was superior to COT in preventing reintubation (OR 0.52, 95% CI 0.34-0.79, P = .002) and in reducing the incidence of secondary outcomes such as mechanical ventilation rates and escalation of respiratory support. However, when compared with NIMV, HFNC was not superior in preventing either the primary (OR 0.96; 95% CI 0.77-1.28, P = .97) or secondary outcomes.
In 2016, Roca et al 26 studied predictors of HFNC success in preventing respiratory failure in patients with pneumonia. The ROX index (ratio of SpO 2 /FiO 2 to respiratory rate) was used to predict success of HFNC therapy. A total of 157 patients with pneumonia and hypoxemic respiratory failure were enrolled, and 28% of these patients (44 patients) ultimately required mechanical ventilation despite HFNC therapy. However, a ROX index <4.88 after 12 hours of HFNC therapy was highly predictive of a lesser need for mechanical ventilation (hazard ratio 0.27, 95% CI 0.121-0.62, P = .002). This study suggests that the ROX index may be quite useful in identifying patients who are at risk of HFNC failure.
Although these studies failed to analyze a specific cohort of cardiothoracic patients with acute hypoxemic respiratory failure, appropriately applied HFNC therapy may decrease reintubation rates and increase mechanical ventilator-free days while allowing time for improved enteral nutrition and early mobilization. A mortality benefit from the use of HFNC cannot be anticipated and concerns for potential oxygen toxicity and unnecessarily delayed reintubation must be considered with more prolonged use of this treatment modality. 25, [27] [28] [29] [30] The ROX index has been shown to be useful in nonsurgical patients with pneumonia. However, further studies in surgical populations will be necessary to better define the role of all 3 therapies-COT, HFNC, and NIMV-in the postoperative setting.
Targeted Temperature Management After Cardiac Arrest
The term therapeutic hypothermia has largely been replaced by "targeted temperature management" (TTM) after the meeting of 5 major professional physician societies in 2011. 31, 32 TTM is used to treat elevations in intracranial pressure, provide neuroprotection from hypoxic/ ischemic encephalopathy, and most commonly, for cardiac arrest victims. However, the use of TTM has come under scrutiny recently with some authors advocating a moratorium on the practice. 33 Earlier studies examining the role of TTM showed improvement in survival and favorable neurologic recovery in patients with out-of-hospital cardiac arrest (OHCA) due to ventricular fibrillation. 34, 35 However, the evidence for TTM for nonshockable (asystole or pulseless electrical activity) rhythms and in-hospital cardiac arrest has been less robust. Despite these discrepancies, international guidelines, including the 2017 French guidelines, 36 continue to recommend the use of TTM after cardiac arrest regardless of the cause. 37 However, a number of studies were also published this past year regarding the use of TTM in specific settings and populations including in-hospital and intraoperative cardiac arrests and the elderly. Attempts were also made to identify the ideal duration of TTM. A thorough review of these data is warranted as some of it may contradict current guideline recommendations.
TTM and In-Hospital Cardiac Arrest
Chan et al 38 published a 2016 study using the large national registry called "Get With The Guidelines Resuscitation Registry." The study included 26 183 patients who suffered an in-hospital cardiac arrest. 38 The authors found that after propensity score matching, therapeutic hypothermia was associated with lower survival to hospital discharge. This finding held true for both shockable and nonshockable cardiac arrest rhythms. When follow-up was extended to 1 year, there remained no survival advantage. Furthermore, therapeutic hypothermia was also associated with lower rates of favorable neurological survival. The authors concluded that their findings did not support current use of therapeutic hypothermia for patients with in-hospital cardiac arrest. 38 Another trial studying TTM for in-hospital cardiac arrest was conducted in children. 39 The data showed no significant differences between the hypothermic and normothermic groups in terms of neurobehavioral function and 1-year survival. Enrollment in this trial was ultimately halted due to futility.
In a specific subset of in-hospital cardiac arrest patients, those having intraoperative cardiac arrest, a multicenter, retrospective French study examined outcomes for patients having this high-risk event. Patients were assigned to receive or not receive TTM based on institutional practice. 40 The first recordable rhythm was asystole in 44% of patients, pulseless electrical activity in 36% and ventricular fibrillation/tachycardia in 20%. The authors found that TTM use was not associated with a favorable 1-year outcome. However, one or more defibrillations before return of spontaneous circulation was positively associated with a favorable functional outcome at 1 year. Hence, the type and quality of cardiopulmonary resuscitation effort may be more important than the therapeutic hypothermia given after an intraoperative cardiac arrest.
The Elderly With Out-of-Hospital Cardiac Arrest and TTM
The benefits of TTM on elderly patients suffering OHCA was evaluated this past year in 2 studies. One study used the Cardiac Arrest Registry to Enhance Survival (CARES) 41 data set registry and analyzed approximately 3000 patients aged 75 years or older. 42 Almost half of the patients received TTM. Factors associated with receiving TTM therapy after OHCA in this study were being male, a documented shockable rhythm and a witnessed event. The authors found no association between TTM application and in-hospital mortality among patients who had an initial rhythm of ventricular fibrillation. Furthermore, patients with a nonshockable rhythm receiving TTM had higher odds of in-hospital mortality. Overall, propensity score results showed a modest association with TTM and increased mortality.
The other study was a retrospective, single-center study of 295 survivors of OHCA admitted to an ICU. Using stepwise, multivariate regression analysis per 10 years of age, the authors corroborated the CARES findings that younger age predicted good cerebral performance and while elderly patients derived much less benefit from this aggressive therapy. 43 These studies suggest future randomized trials are needed to evaluate the effects of TTM in elderly OHCA survivors.
Duration of TTM
While international guidelines recommend the use of TTM following cardiac arrest, the duration of this management is not clearly stated. The International Liaison Committee on Resuscitation (ILCOR) task force recommends TTM for adults with OHCA with an initial shockable rhythm at a constant temperature between 32°C and 36°C for at least 24 hours. 44 However, many study protocols and institutional guidelines routinely expand this time period.
This year, Kirkegaard et al 45 undertook an international, multicenter randomized controlled trial to resolve this controversy. This study did not show a difference between TTM at 33°C for 48 versus 24 hours, when comparing 6-month neurologic outcomes. Overall mortality at 6 months was also not significantly improved with the longer duration of TTM. Furthermore, the proportion of patients with one or more adverse events, particularly hypotension, was significantly higher in the 48-hour group. While rates of pneumonia and bleeding were similar regardless of the duration of TTM, severe bleeding was more common in the 24-hour group. The authors concluded that TTM for 48 hours did not significantly improve 6-month neurologic outcome compared with TTM for 24 hours, but that there were possible power limitations in the current study and further research may be warranted.
The data published in 2017 call into question the use of TTM in patients undergoing in-hospital cardiac arrest, intraoperative or otherwise, and in the elderly. The appropriate duration of TTM also appears to be in evolution. Thoughtfully designed randomized studies are needed to develop datadriven guidelines for this important therapeutic option.
Conclusion
In the past year, many high-quality studies contributed new knowledge to the field of cardiothoracic critical care. A summary of this year's noteworthy literature can be found in Table 1 . Ongoing research in these areas and others continue to advance the care of our patients.
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